Antibodies against A. phagocytophilum outer membrane protein P44 (mAb 5C11),124 dog anti-E. chaffeensis,122 rabbit anti-E. chaffeensis P28,52 ACT/actin (Sigma, A2066), Etf-1,43 BECN1 (Cell Signaling Technology, 3738), PIK3C3/VPS34 (Cell Signaling Technology, 4263), ATG5 (Abcam ab78073), MAP1LC3B/LC3B (NovusBio, NB100-2220), poly-ubiquitinated proteins (Enzo Life Sciences, FK1, BML-PW8805), mono- and poly-ubiquitinated proteins (Enzo Life Sciences, FK2, BML-PW8810), mouse anti-TUBA/α-tubulin (Santa Cruz Biotechnology, sc-5286), MYC/c-Myc (BioLegend, 901501), FLAG M2 (Sigma, F1804), RAB5,125 GFP (mAb Clone B-2; Santa Cruz Biotechnology, sc-9996), anti-VirB6-2,40 Alexa Fluor (AF) 350-conjugated goat anti-mouse IgG (Invitrogen, A-21049), AF555-conjugated goat anti-mouse IgG (Invitrogen, A-21427), and AF488-conjugated goat anti-rabbit IgG (Invitrogen, A-11008) or anti-mouse IgG (Invitrogen, A-11029) were used.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.